138 related articles for article (PubMed ID: 36748802)
1. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.
Hill JA; Kiem ES; Bhatti A; Liu W; Keane-Candib J; Fitzpatrick KS; Boonyaratanakornkit J; Gardner RA; Green DJ; Maloney DG; Turtle CJ; Smith JM; Gimferrer I; Blosser CD; Jackson SW
Am J Transplant; 2023 Mar; 23(3):416-422. PubMed ID: 36748802
[TBL] [Abstract][Full Text] [Related]
2. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma.
Josyula S; Pont MJ; Dasgupta S; Song X; Thomas S; Pepper G; Keane-Candib J; Stevens-Ayers TL; Ochs HD; Boeckh MJ; Riddell SR; Cowan AJ; Krantz EM; Green DJ; Hill JA
Transplant Cell Ther; 2022 Jun; 28(6):304.e1-304.e9. PubMed ID: 35288345
[TBL] [Abstract][Full Text] [Related]
3. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
Hill JA; Krantz EM; Hay KA; Dasgupta S; Stevens-Ayers T; Bender Ignacio RA; Bar M; Maalouf J; Cherian S; Chen X; Pepper G; Riddell SR; Maloney DG; Boeckh MJ; Turtle CJ
Blood Adv; 2019 Nov; 3(22):3590-3601. PubMed ID: 31743392
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Kampouri E; Ibrahimi SS; Xie H; Wong ER; Hecht JB; Sekhon MK; Vo A; Stevens-Ayers TL; Green DJ; Gauthier J; Maloney DG; Perez A; Jerome KR; Leisenring WM; Boeckh MJ; Hill JA
Clin Infect Dis; 2024 Apr; 78(4):1022-1032. PubMed ID: 37975819
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies.
Zhang Z; Markmann C; Yu M; Agarwal D; Rostami S; Wang W; Liu C; Zhao H; Ochoa T; Parvathaneni K; Xu X; Li E; Gonzalez V; Khadka R; Hoffmann J; Knox JJ; Scholler J; Marcellus B; Allman D; Fraietta JA; Samelson-Jones B; Milone MC; Monos D; Garfall AL; Naji A; Bhoj VG
Cell Rep Med; 2023 Dec; 4(12):101336. PubMed ID: 38118406
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
8. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
9. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis.
Mohyuddin GR; Atieh T; Ahmed N; Sborov D; McClune B; Abdallah AO; Goodman AM; Aziz M; Allen I; Prasad V
Eur J Cancer; 2021 Oct; 156():164-174. PubMed ID: 34454318
[TBL] [Abstract][Full Text] [Related]
10. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
11. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes following CAR T cell therapy: what we know so far.
Cappell KM; Kochenderfer JN
Nat Rev Clin Oncol; 2023 Jun; 20(6):359-371. PubMed ID: 37055515
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
15. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA; Seo SK
Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
[TBL] [Abstract][Full Text] [Related]
16. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
Smith EL; Staehr M; Masakayan R; Tatake IJ; Purdon TJ; Wang X; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Riviere I; Liu C; Brentjens RJ
Mol Ther; 2018 Jun; 26(6):1447-1456. PubMed ID: 29678657
[TBL] [Abstract][Full Text] [Related]
17. CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.
Gupta S; Simic M; Sagan SA; Shepherd C; Duecker J; Sobel RA; Dandekar R; Wu GF; Wu W; Pak JE; Hauser SL; Lim W; Wilson MR; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36657993
[TBL] [Abstract][Full Text] [Related]
18. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
[TBL] [Abstract][Full Text] [Related]
20. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
